These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34214236)

  • 1. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.
    Benafif S; Ni Raghallaigh H; McGrowder E; Saunders EJ; Brook MN; Saya S; Rageevakumar R; Wakerell S; James D; Chamberlain A; Taylor N; Hogben M; Benton B; D'Mello L; Myhill K; Mikropoulos C; Bowen-Perkins H; Rafi I; Ferris M; Beattie A; Kuganolipava S; Sevenoaks T; Bower J; Kumar P; Hazell S; deSouza NM; Antoniou A; Bancroft E; Kote-Jarai Z; Eeles R
    BJU Int; 2022 Mar; 129(3):325-336. PubMed ID: 34214236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.
    Castro E; Mikropoulos C; Bancroft EK; Dadaev T; Goh C; Taylor N; Saunders E; Borley N; Keating D; Page EC; Saya S; Hazell S; Livni N; deSouza N; Neal D; Hamdy FC; Kumar P; Antoniou AC; Kote-Jarai Z; ; Eeles RA
    Oncologist; 2016 Jun; 21(6):716-22. PubMed ID: 27151655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
    Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Karow DS; Mills IG; Andreassen OA; Dale AM;
    BMJ; 2018 Jan; 360():j5757. PubMed ID: 29321194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
    Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
    Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
    Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
    BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI.
    Marsden T; Lomas DJ; McCartan N; Hadley J; Tuck S; Brown L; Haire A; Moss CL; Green S; Van Hemelrijck M; Coolen T; Santaolalla A; Isaac E; Brembilla G; Kopcke D; Giganti F; Sidhu H; Punwani S; Emberton M; Moore CM;
    BMJ Open; 2021 Sep; 11(9):e048144. PubMed ID: 34593491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.
    Jiang H; Liu F; Wang Z; Na R; Zhang L; Wu Y; Zheng J; Lin X; Jiang D; Sun J; Zheng SL; Ding Q; Xu J
    Prostate; 2013 Nov; 73(15):1651-9. PubMed ID: 23868750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Search for genetic factor association with cancer-free prostate-specific antigen level elevation on the basis of a genome-wide association study in the Korean population.
    Choe EK; Lee Y; Cho JY; Choi SH; Park B; Lee JE; Cho EY
    Eur J Cancer Prev; 2018 Sep; 27(5):453-460. PubMed ID: 28471803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
    Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
    Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.
    Akamatsu S; Terada N; Takata R; Kinoshita H; Shimatani K; Momozawa Y; Yamamoto M; Tada H; Kawamorita N; Narita S; Kato T; Nitta M; Kandori S; Koike Y; Inazawa J; Kimura T; Kimura H; Kojima T; Terachi T; Sugimoto M; Habuchi T; Arai Y; Yamamoto S; Matsuda T; Obara W; Kamoto T; Inoue T; Nakagawa H; Ogawa O
    JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35118230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
    Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
    JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic predisposition to prostate cancer.
    Benafif S; Eeles R
    Br Med Bull; 2016 Dec; 120(1):75-89. PubMed ID: 27941040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme.
    Alterbeck M; Järbur E; Thimansson E; Wallström J; Bengtsson J; Björk-Eriksson T; Bjartell A; Bratt O; Jiborn T; Arnsrud Godtman R
    Eur Urol Focus; 2022 Nov; 8(6):1568-1574. PubMed ID: 35811285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
    Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
    BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.